Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This research is being done to assess the therapeutic efficacy and safety of a promising
regimen (Venetoclax combined with Decitabine/Azacitidine and Aclarubicin) versus Venetoclax
combined with Decitabine/Azacitidine in treatment-naive elderly patients with Acute Myeloid
Leukemia.
This study involves the following:
Venetoclax, Decitabine/Azacitidine, Aclarubicin (investigational combination) Venetoclax and
Decitabine/Azacitidine (per standard of care)
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborators:
Huai'an First People's Hospital The Affiliated Jiangning Hospital of Nanjing Medical University Yancheng First People's Hospital